Weekly Sepsis Research Analysis
This week’s sepsis literature highlights mechanistic insights linking lectin- and lipid-mediated host responses to outcomes, rigorous device- and treatment-oriented evidence that informs bedside practice, and several translational innovations (antimicrobial polymers, GNN diagnostics, source-tracking) that could change prevention and therapy. Notable systems-level work shows Mrc1 (CD206) shapes the circulating mannose-glycoproteome with relevance to sepsis outcome, while HDL–SR-B1 and CETP inhibi
Summary
This week’s sepsis literature highlights mechanistic insights linking lectin- and lipid-mediated host responses to outcomes, rigorous device- and treatment-oriented evidence that informs bedside practice, and several translational innovations (antimicrobial polymers, GNN diagnostics, source-tracking) that could change prevention and therapy. Notable systems-level work shows Mrc1 (CD206) shapes the circulating mannose-glycoproteome with relevance to sepsis outcome, while HDL–SR-B1 and CETP inhibition reduce endotoxin-driven inflammation in mice. A high-quality meta-analysis questions many continuous cardiac output monitors in septic shock and prioritizes calibrated pulse-contour performance, directly informing hemodynamic monitoring choices.
Selected Articles
1. Mrc1 (MMR, CD206) controls the blood proteome in reducing inflammation, age-associated organ dysfunction and mortality in sepsis.
Using glycoproteomic enrichment and genetic models, this study shows that the mannose receptor Mrc1 (CD206) governs the abundance of >200 circulating mannosylated proteins in mice; Mrc1 dysfunction maps to inflammatory and organ-dysfunction pathways that overlap with human sepsis signatures, suggesting a systems-level mechanism linking lectin receptor biology to sepsis outcomes.
Impact: Reveals a previously underappreciated, targetable mechanism by which lectin receptor function shapes the circulating glycoproteome and links directly to sepsis-associated inflammation and mortality; provides a new axis for biomarker interpretation and therapeutic exploration.
Clinical Implications: If validated in humans, measuring Mrc1-dependent mannosylated glycoproteins could refine prognostic panels and patient selection; modulating lectin receptor pathways may be a novel host-directed strategy to reduce inflammation and organ failure in sepsis.
Key Findings
- Mrc1 deficiency leads to accumulation of >200 endogenous mannosylated plasma proteins at steady state.
- Accumulated proteins map to inflammatory and age-associated organ dysfunction pathways overlapping human sepsis signatures.
- Circulating Mrc1 levels rise in sepsis proportionally to mannosylated protein accumulation, linking receptor status to proteome shifts.
2. Cardiac output monitors in septic shock: do they deliver what matters? A systematic review and meta-analysis.
Systematic review/meta-analysis of 26 prospective studies (1,323 patients, 37 device-reference datasets) found pooled percentage error across cardiac output monitors was 49% (threshold <30%), with calibrated pulse contour analysis achieving acceptable error (PE 25%) while many uncalibrated devices (bioimpedance, bioreactance) performed poorly. Trending, precision, and time-response metrics were rarely reported, limiting clinical interpretability.
Impact: Directly informs bedside hemodynamic monitoring: challenges reliance on many continuous CO devices in septic shock and reframes validation standards to include trending and time-response—metrics that matter for clinicians making rapid hemodynamic decisions.
Clinical Implications: Prefer calibrated pulse contour systems for continuous CO monitoring when needed and exercise caution with uncalibrated pulse contour, bioimpedance, or bioreactance devices; future validation studies should mandate trending, precision, and latency metrics linked to patient-centered outcomes.
Key Findings
- Pooled percentage error across devices was 49%, above the 30% interchangeability threshold.
- Calibrated pulse contour analysis achieved acceptable agreement (PE 25%); uncalibrated PCA, thoracic bioimpedance, and bioreactance had poor agreement (PE ≥52%).
- Only 3 of 15 datasets assessing trending achieved concordance ≥90%; heterogeneity (I²>80%) was high.
3. High-density lipoprotein attenuates lipopolysaccharide-induced IL-1β activation via scavenger receptor class B type 1.
Mechanistic cellular and murine studies show HDL promotes SR-B1-dependent internalization and degradation of LPS in macrophages, thereby suppressing IL-1β activation; pharmacologic CETP inhibition (anacetrapib) increased HDL, reduced tissue injury and IL-1β, and improved survival in endotoxemia models—supporting an actionable lipid–immune pathway.
Impact: Defines a clear, druggable lipid–innate immune mechanism (HDL–SR-B1–LPS handling) with pharmacologic validation (CETP inhibitor) that improved survival in preclinical endotoxemia, motivating translational testing in polymicrobial sepsis.
Clinical Implications: Supports investigating HDL-raising approaches (CETP inhibitors, HDL mimetics) or SR-B1 pathway modulation as adjunctive strategies in sepsis; careful translation is required because endotoxemia models differ from human sepsis.
Key Findings
- HDL inhibited LPS-induced IL-1β activation in macrophages and in vivo.
- SR-B1 was required for this effect; SR-B1 knockdown reduced IL-1β production and SR-B1 internalization trafficked LPS to endosome–lysosome degradation.
- CETP inhibition (anacetrapib) increased HDL, attenuated pulmonary and hepatic injury, reduced IL-1β and improved survival after LPS.